Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
1.049
-0.061 (-5.50%)
At close: Aug 14, 2026, 4:00 PM EDT
1.049
0.00 (0.04%)
After-hours: Aug 14, 2026, 7:42 PM EDT
Revelation Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
Gemini, a novel anti-inflammatory therapy, is advancing to a pivotal adaptive phase II/III trial for acute kidney injury, with FDA support for a composite endpoint and efficient study design. Strong clinical and preclinical data support broad potential, and cash runway extends into Q1 2027.